Epitalon vs DSIP, SS-31, NAD+ and Endoluten related to longevity

Epitalon, DSIP, SS-31, NAD+, and Endoluten are often grouped together under terms such as „longevity” or „biohacking,” but they are not equivalent compounds and do not address the same research questions. Epitalon has been studied primarily in the context of telomere biology and the pineal gland, DSIP in sleep research, SS-31/elamipretide in the context of mitochondrial function, NAD+ in cellular metabolism, and Endoluten as a pineal-derived peptide complex for which the evidence base is significantly less clearly indexed. [1–8]

The broad category of „longevity-related compounds” can conceal significant differences in chemistry, mechanism of action, quality of evidence, and degree of clinical development. Epitalon is a defined tetrapeptide Ala-Glu-Asp-Gly (AEDG). DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. SS-31, currently more commonly referred to clinically as elamipretide, is a mitochondria-targeted tetrapeptide that interacts with cardiolipin in the inner mitochondrial membrane. NAD+ is not a peptide: nicotinamide adenine dinucleotide is an essential metabolic cofactor involved in redox reactions, energy metabolism, and signaling. Endoluten is generally described in the tradition of Khavinson's products as a low-molecular-weight peptide complex derived from the pineal gland, rather than as a single, chemically defined peptide. [1,6–9]

These differences have significant consequences for the interpretation of evidence. A sleep study involving DSIP cannot be used to confirm the effects of Epitalon. Elamipretide research in mitochondrial diseases cannot be treated as evidence of the efficacy of a general „mitochondrial peptide stack.” Human studies showing that nicotinamide riboside or nicotinamide mononucleotide can increase the levels of NAD-related metabolites do not prove that intravenous NAD+ extends life. Similarly, results concerning Epitalon or the older pineal extract Epithalamin should not be automatically attributed to Endoluten just because all three appear in related discussions concerning pineal peptides.

Therefore, the most useful comparison is not to ask which compound is the „best longevity peptide,” but rather which biological question was actually investigated for each compound, what level of evidence exists, and whether these results have translated into clinically relevant effects in humans.

How does Epitalon compare to DSIP?

Epitalon and DSIP are structurally and scientifically distinct peptides. Epitalon is an AEDG tetrapeptide studied mainly in the context of telomere biology, pineal gland function, melatonin, chromatin, and aging models, whereas DSIP is a WAGGDASGE nonapeptide studied primarily in relation to sleep physiology and neuroendocrine effects. DSIP has been the subject of direct human sleep studies, although their results have been limited and inconsistent. [1–5]

Epitalon is composed of four amino acids—Ala-Glu-Asp-Gly—and originates from Khavinson’s research program on pineal peptides. Its most recognizable evidence includes studies on telomerase and telomeres in cultured human cells, age-related melatonin regulation in animal studies and limited human trials, effects on chromatin in cultured lymphocytes, and lifespan or cancer-related outcomes in animal models. [1,10–13] The preclinical literature is relatively extensive, but contemporary controlled data on human efficacy remain limited.

DSIP has a completely different structure and research history. Schoenenberger and coworkers identified it as the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated as WAGGDASGE, during research on a sleep-related factor in rabbits. [2] The term „delta sleep-inducing peptide” originated from early electrophysiological experiments in which this substance was linked to slow-wave, or delta, EEG activity.

Unlike many research peptides currently discussed within longevity communities, DSIP was directly tested in humans for sleep several decades ago. In a 1981 double-blind, crossover study involving six healthy volunteers, intravenous administration of DSIP was associated with an increase in the amount of sleep during the observation period and certain changes in subsequent nighttime sleep measurements. [3]

Later research, however, made the clinical picture much less convincing. A double-blind study involving 16 people with chronic insomnia showed slightly greater sleep efficiency and shorter sleep latency compared to placebo, but the researchers emphasized that the statistically significant changes were small, resulted in part from changes in the placebo group, and were not accompanied by consistent improvements in other objective or subjective outcomes. The authors concluded that short-term use of DSIP is unlikely to provide significant therapeutic benefits in chronic insomnia. [4]

Another controlled clinical trial also reported an increase in total sleep time and NREM sleep, but found that the observed improvement was of little clinical significance, partly because significant differences between the groups were already present at baseline. [5]

Detailed sleep results are more complex than the peptide's name suggests. In an early insomnia experiment involving six people, the apparent sleep-promoting effect appeared primarily in the second hour, rather than causing immediate and predictable sedation. Later controlled studies showed that the increase in NREM sleep resulted mainly from an increase in stage 2 sleep, while stages 3 and 4 of slow-wave sleep and REM sleep did not consistently increase. In an insomnia study involving 16 people, moderate objective changes were not accompanied by an improvement in subjective sleep quality. [3–5]

This difference between objective and subjective outcomes is significant. Polysomnography can detect changes in sleep latency, sleep efficiency, awakenings, and sleep stage distribution, but a statistically measurable change does not necessarily mean that sleep is perceived as more restorative or that daytime functioning improves. Historical literature regarding DSIP has not demonstrated sustained improvement in contemporary clinical outcomes, such as insomnia severity, daytime alertness, quality of life, or sustained remission.

The mechanism of action also remains uncertain. The existence of a dedicated DSIP receptor or a single signaling pathway has not been confirmed. Experimental studies suggest possible modulation of GABAergic, glutamatergic, monoaminergic processes, and the hypothalamic-pituitary-adrenal axis, but a significant portion of this evidence comes from animal tissue studies, isolated neurons, or specialized neuroendocrine experiments, rather than unambiguous human receptor pharmacology. [17]

Statements regarding the half-life of DSIP require similar caution. The frequently repeated value of about 15 minutes comes from in vitro degradation studies in brain tissue rather than a validated human plasma pharmacokinetic study. Therefore, it cannot be reliably used to predict how fast DSIP acts, how long the effect lasts, or how often administration would be necessary.

The route of administration used in clinical studies represents another significant limitation. Main human sleep studies utilized intravenously administered DSIP under supervision. These studies do not determine the bioavailability, efficacy, or safety of modern subcutaneous injections, nasal sprays, or oral products. There are no direct comparative human studies showing that a nasal or subcutaneous formulation reproduces the exposure or sleep effects observed after historical intravenous administration.

Native DSIP should also be distinguished from phospho-DSIP. Phospho-DSIP is a modified analog phosphorylated at the serine residue at position 7. In studies on rats, changes in slow-wave sleep and paradoxical sleep, i.e., REM, were reported after the application of this analog, but these results cannot be automatically attributed to unmodified DSIP or translated into clinical effects in humans.

This creates an unusual comparative situation. DSIP has more direct human sleep studies than Epitalon, but this literature is old, relies on small samples, and yields inconsistent results. Epitalon's sleep-related evidence is less direct and focuses more on melatonin and circadian rhythm regulation rather than polysomnographically measured insomnia outcomes.

Therefore, it would not be correct to describe Epitalon and DSIP as two versions of the same „sleep peptide.” Their areas of overlap are limited and mainly concern the broader field of neuroendocrine research and circadian rhythms.

Do Epitalon and DSIP address the same research questions?

Only to a limited extent. DSIP research is more concerned with direct issues related to sleep architecture, sleep latency, EEG activity, and neurophysiological regulation, whereas Epitalon research focuses more on pineal gland function, melatonin rhythms, telomerase, gene regulation, and the biology of aging. Both areas intersect with circadian rhythm physiology, but their primary experimental goals and evidentiary bases differ significantly. [1,3–5,14–16]

The most clearly overlapping area is sleep and circadian biology, although even here the measured outcomes vary.

DSIP studies have often evaluated actual sleep parameters. Human studies have utilized objective or partially objective endpoints such as total sleep time, sleep efficiency, sleep latency, NREM sleep, and other polysomnographic parameters. [3–5] Early animal studies also assessed EEG activity and individual sleep stages. For this reason, DSIP can reasonably be described as a peptide with a direct history of sleep research, even though clinical evidence has not confirmed its efficacy as a modern treatment for insomnia.

In these studies, DSIP did not cause a single, consistent pattern of changes in sleep architecture. Some early experiments suggested longer or less interrupted sleep, whereas later controlled studies showed weak or statistically insignificant effects. When an increase in NREM sleep was observed, the change did not consistently involve deeper slow-wave sleep. Results regarding REM sleep were also inconsistent. As a result, DSIP cannot be accurately described as a compound proven to increase „deep sleep,” restore a specific sleep stage, or act like a conventional sleeping pill. [3–5]

Epitalon research typically approaches the issue of sleep at an earlier level of regulation. In studies on elderly rhesus macaques, changes in nocturnal or evening melatonin levels and certain aspects of the circadian cortisol rhythm were noted after exposure to Epithalon. [14] In a study on rat pinealocytes, increased expression or activation of molecular elements involved in melatonin synthesis was found, along with increased melatonin production in culture. [15]

However, the literature concerning Epitalon also contains conflicting results. Djeridane and coworkers studied isolated pineal glands of young and old rats and found no significant increase in basal or stimulated melatonin secretion after exposure to AEDG. [16] For this reason, it is not appropriate to describe Epitalon simply as a reliable melatonin-increasing compound.

More importantly, melatonin concentration is not the same result as sleep quality. The literature regarding Epitalon does not confirm significant improvement in humans in terms of:

sleep efficiency;

exacerbations of insomnia;

snu REM;

deep or slow-wave sleep;

total sleep time;

night awakenings; nor

daytime functioning resulting from improved sleep.

For comparison, DSIP studies measured some of these sleep parameters directly, although the results were not consistently clinically significant.

Their broader research profiles differ even more. Epitalon has been the subject of research on human cells regarding telomerase and telomere length, whereas telomere maintenance is not a characteristic area of research for DSIP. DSIP has a broader historical neurophysiological literature concerning neurotransmission, stress response, hormonal regulation, and models related to withdrawal syndrome, but these findings do not support its action as a geroprotective compound. [17]

Neuroendocrine literature includes experiments concerning ACTH, cortisol, corticosterone, and responses to stress-related stimuli. These results suggest that DSIP may influence the hypothalamic-pituitary-adrenal axis under specific experimental conditions, but they do not prove that it reliably lowers cortisol levels in humans. Similarly, proposed effects involving GABA, glutamate, NMDA signaling, serotonin, or opioid-related systems remain mechanistic observations rather than proof of a single, consistent therapeutic mechanism. [17]

Safety evidence is also too limited to support claims for longevity use. Historical human exposure has been short-term and mainly involved intravenous administration. In some clinical settings, transient headaches, nausea, dizziness, sweating, and hypotension have been reported, while a few small sleep studies have reported few or no adverse effects. These results do not establish long-term safety and do not account for the additional risks related to identity, purity, sterility, endotoxins, and contaminants in unapproved investigational products.

Epitalon can therefore be more accurately characterized as a research peptide associated with aging, the pineal gland, and telomeres, with some overlap into circadian rhythm research, whereas DSIP is primarily a sleep- and neuroregulation-related research peptide that was later incorporated into the longevity discussion.

A more detailed discussion of Epitalon and circadian rhythm biology can be found in the article Epitalon Sleep Research: Melatonin, Circadian Rhythm and Timing.

How does Epitalon compare to SS-31?

Epitalon and SS-31 address fundamentally different areas of biology. Epitalon is studied primarily in the context of telomeres, the pineal gland, and aging-related pathways, whereas SS-31—elamipretide—is a mitochondria-targeted tetrapeptide that interacts with cardiolipin and has undergone numerous human clinical trials. Elamipretide currently has FDA accelerated approval for a specific mitochondrial disease, rather than for general longevity. [1,6,18–23]

SS-31 is also known as elamipretide, and was previously designated as Bendavia or MTP-131. Although both Epitalon and SS-31 are tetrapeptides, their shared number of amino acids constitutes almost the entirety of their similarity.

Elamipretide was developed based on mitochondrial biology. Mechanistic studies have demonstrated interactions with cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. Experimental studies have shown that SS-31 can influence the interaction of cytochrome c with cardiolipin, preserve electron transfer function, and improve the efficiency of mitochondrial ATP synthesis under appropriate experimental conditions. [18]

Epitalon has sometimes been discussed in the context of oxidative stress and mitochondrial function, but mitochondrial cardiolipin is not its primary mechanistic target. Its research program focuses instead on telomerase, chromatin, melatonin, aging physiology, and transcription-related mechanisms. [1]

The difference in clinical development is even greater.

Elamipretide has been evaluated in randomized controlled human trials across several different disease states. A dose-escalation study in adults with primary mitochondrial myopathy demonstrated a dose-dependent improvement in the 6-minute walk test distance following short-term treatment, although several other outcomes did not differ significantly, and the authors deemed larger trials necessary. [19]

A subsequent randomized crossover study in primary mitochondrial myopathy showed no consistent benefit in the broader clinical program, demonstrating that even a mechanism-targeted mitochondrial drug can yield mixed clinical results. [20]

Among patients with heart failure with reduced ejection fraction in the phase 2 PROGRESS-HF trial, 71 participants were randomized to placebo or one of two doses of elamipretide for 28 days. Elamipretide was well tolerated, but did not significantly improve the primary left ventricular structural endpoint compared with placebo. [21]

Other human studies have yielded more promising mechanistic results. Among 39 older adults selected for impaired mitochondrial function, a randomized, double-blind study showed that a single exposure to elamipretide increased, compared with placebo, the parameter of skeletal muscle mitochondrial capacity to produce ATP. [22]

A significant regulatory development occurred in September 2025, when the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg. Barth syndrome is a rare mitochondrial disorder associated with abnormal cardiolipin metabolism. The approval was based on a very small clinical program and requires confirmatory data; it should not be interpreted as FDA approval of elamipretide in the context of aging or longevity.

This gives SS-31/elamipretide a much more advanced clinical development profile in humans than Epitalon in the field of mitochondrial diseases. However, this does not confirm elamipretide as a human life-extending drug.

The difference can be summarized as follows:

Epitalon → telomere/pineal gland/aging research

SS-31/elamipretide → mitochondrial cardiolipin and bioenergetics research

None of these evidence bases confirm an overall extension of human life.

How does Epitalon compare to NAD+?

Epitalon and NAD+ are fundamentally different compounds: Epitalon is a synthetic tetrapeptide studied experimentally in telomere and pineal gland biology, whereas NAD+ is an endogenous dinucleotide essential for cellular redox reactions, energy metabolism, and signaling. Strategies targeting NAD have a much more extensive contemporary human research literature, particularly in the case of NR and NMN, but the demonstrated anti-aging benefits remain limited. [1,7,24–27]

The first important difference is the chemical structure: NAD+ is not a peptide.

Nicotinamide adenine dinucleotide is a cellular coenzyme involved in electron transfer and energy metabolism. It also serves as a substrate for enzymes such as sirtuins, PARPs, and processes involving CD38, linking NAD metabolism to DNA repair, stress responses, metabolism, and the biology of aging.

This creates a certain conceptual similarity to Epitalon, as both compounds are discussed in relation to cellular aging, but their fundamental mechanisms are very different.

The best-known mechanistic findings regarding Epitalon include the activation of telomerase or telomere elongation in human cells, observations related to melatonin, chromatin changes, and hypotheses concerning gene regulation. [10–13]

NAD+-targeted aging research focuses more on cellular energy metabolism and metabolic signaling. Preclinical studies have repeatedly shown that increasing NAD availability can affect mitochondrial function, glucose and lipid metabolism, inflammatory signaling, and aging-related physiology. However, translating these findings into effects in humans has been significantly less spectacular. [24–27]

The main source of misunderstanding is the fact that NAD+, NR, and NMN themselves are not interchangeable interventions.

Most modern human clinical data concerns precursors—nicotinamide riboside and nicotinamide mononucleotide—rather than intravenous NAD+ itself. Human studies have repeatedly shown that oral NR or NMN can increase the levels of NAD-related metabolites in the blood and certain tissues, confirming a clear effect on the biochemical target. [24–27]

Evidence regarding significant functional effects is much less consistent.

A review published in 2025 in Nature Metabolism stated that while NAD precursor supplementation has strong support in preclinical studies, clinical efficacy regarding healthy aging remains limited so far, and human results are scarce and tissue-dependent. [24]

A 2026 systematic review evaluated 113 studies, including 33 human interventions. It found that oral NR and NMN generally increased NAD-related biomarkers and were relatively well tolerated over short- and medium-term periods, but the effects on functional, vascular, metabolic, and other healthspan-related outcomes were mixed and often null or limited to specific endpoints. The review did not identify any eligible outcome studies on intravenous or intramuscular NAD+ administration alone for anti-aging or wellness applications. [25]

The statement that „NAD+ has stronger evidence in humans than Epitalon” therefore requires clarification.

It can reasonably be stated that NAD-targeted biology, especially NR and NMN supplementation, has been studied in a greater number of modern randomized human trials.

However, it is not correct to state that it has been proven that NAD+ slows down aging or extends human life.

Both compounds also focus on different endpoints. Epitalon has more direct experimental evidence regarding telomere maintenance, whereas NAD+ precursors have more human biomarker research related to metabolism and NAD. Neither has been shown to extend human lifespan.

For a more detailed comparison of NAD-related compounds and peptide-based approaches, see the directly linked article NAD+ vs Other Longevity Compounds.

How does Epitalon compare to Endoluten?

Epitalon is a chemically defined synthetic tetrapeptide AEDG with identifiable peer-reviewed literature, whereas Endoluten is generally described as a low molecular weight pineal-derived peptide complex rather than a single defined molecule. Direct peer-reviewed evidence indexed specifically under the name Endoluten is limited, therefore results concerning Epitalon or Epithalamin should not be automatically attributed to Endoluten.

This comparison requires special caution because Endoluten, Epitalon, and Epithalamin are often equated with each other in online materials.

Epitalon is chemically unambiguous. It is Ala-Glu-Asp-Gly, or AEDG, and its identity can be determined based on sequence and molecular analysis. AEDG was developed based on research involving the older pineal preparation Epithalamin, and was subsequently identified within the pineal polypeptide complex. [1,28]

Epithalamin is something else. It is a complex peptide preparation derived from the bovine pineal gland, rather than a single defined molecule composed of four amino acids. Many older human gerontological and endocrinological research results, widely associated with „pineal peptides,” actually concern Epithalamin rather than Epitalon.

Endoluten introduces an additional level of uncertainty. The trade name is used to refer to a pineal-derived peptide complex, but targeted searches in PubMed have not identified a comparable base of indexed, peer-reviewed primary publications specifically investigating „Endoluten” as a separately characterized intervention.

This distinction is important because three separate claims are often treated as if they were equivalent:

Epithalamin affected result X.

AEDG/Epitalon affected the X result.

Therefore, Endoluten must affect the result of X.

Such a conclusion is not scientifically justified unless the Endoluten preparation itself has been characterized and directly tested.

The same issue applies to claims related to melatonin. Epitalon has animal, primate, and limited human studies related to melatonin. Epithalamin has its own historical endocrinological literature. This does not prove that the commercial Endoluten preparation provides equivalent exposure to peptides, reaches the same tissues, or reproduces the same biological effect.

A reliable evidence base regarding Endoluten should ideally specify:

peptide composition of the preparation;

batch-to-batch reproducibility;

identity and quantity of individual active peptides;

pharmacokinetics specific to oral administration or other routes of administration;

do intact peptides reach the systemic circulation;

results of controlled clinical trials in humans; and

long-term security.

Without this data, Endoluten is best described as a related pineal peptide complex with significantly less directly attributable peer-reviewed evidence than chemically defined AEDG Epitalon.

Were any of these connections studied directly?

No robust peer-reviewed evidence has been identified regarding fixed combinations of Epitalon with DSIP, SS-31, NAD+, or Endoluten. Each of these compounds has been largely studied within its own research program; therefore, claims that the combinations are synergistic, safer, more effective, or better for longevity cannot be confirmed by simply summing up the proposed mechanisms of the individual compounds.

This is particularly important for searched phrases such as „Epithalon + DSIP”, „Epitalon DSIP stack”, „Epitalon and SS-31”, or combinations involving peptides and NAD+.

A search query may indicate market or user interest, but it does not prove that the combination itself has ever been scientifically evaluated.

In the case of Epitalon and DSIP, the theoretical rationale typically stems from their overlap in the biology of circadian rhythms. Epitalon is associated with pineal gland and melatonin research, whereas DSIP has direct historical sleep research. This does not prove that combining them improves sleep more than either of these compounds used separately.

There is no established study showing:

Epitalon alone compared to DSIP alone;

both peptides used together;

appropriately matched placebo control;

polysomnographic results;

pharmacokinetic interactions; nor

connection security.

Similarly, combining Epitalon with SS-31 may seem conceptually attractive because one compound is promoted in the context of broader aging biology, while the other has a direct mitochondrial mechanism. However, there is no direct evidence showing that AEDG enhances the mitochondrial effects of elamipretide or that elamipretide increases the telomere-related effects observed with Epitalon.

The same principle applies to NAD+.

Mitochondria, NAD metabolism, and telomere maintenance participate in the biology of aging, but the biological pathways are interconnected in ways that can be additive, redundant, compensatory, or antagonistic. Mechanistic complementarity is a hypothesis, not proof of synergy.

A rigorous combination experiment would need to compare each intervention separately with their combination under the same experimental conditions. For example, an Epitalon–DSIP study should ideally include a control group, Epitalon alone, DSIP alone, and the combination treatment, with predefined sleep or circadian rhythm outcomes. Similar factorial designs would be required for Epitalon with elamipretide or Epitalon with a NAD-targeting intervention.

Endoluten presents an additional difficulty because it is itself a complex mixture rather than a single fully characterized molecular entity. Combining a defined peptide with a poorly characterized peptide complex further complicates the attribution of biological effects.

Therefore, statements such as „Epitalon and DSIP work synergistically,” „SS-31 complements the Epitalon longevity stack,” or „adding NAD+ enhances the anti-aging effects of Epitalon” require direct evidence, which is currently lacking.

Which compound has the strongest human evidence for individual outcomes?

No single compound has the strongest evidence across all longevity-related outcomes. DSIP has the most direct historical human sleep experiments, elamipretide has the strongest clinical evidence in mitochondrial diseases, NAD precursors have the largest modern human biomarker literature, and Epitalon has characteristic telomere-related evidence from human cell studies. None of them have demonstrated human lifespan extension.

The response changes depending on the measured result.

You

For direct human sleep measurements, DSIP has the most clear-cut evidence among these compounds, as controlled studies have evaluated sleep latency, sleep efficiency, NREM sleep, and related outcomes following DSIP administration. [3–5]

However, the term „strongest” in this context should not be equated with „strong.” The studies were small and old, and subsequent analyses indicated that the observed clinical effects were weak or of limited therapeutic significance.

Epitalon has more evidence related to melatonin and the endocrine physiology of circadian rhythms, but fewer direct data regarding sleep quality in humans.

Melatonin and pineal gland aging

Epitalon has more relevant experimental literature, particularly concerning older monkeys and pineal cell studies. [14–16] Some older human studies have also reported changes in nocturnal melatonin levels in the elderly, although methodological details available in the abstracts are limited.

DSIP should not be automatically classified as a melatonin peptide solely due to its connection to sleep.

Telomerase and telomere maintenance

Epitalon has the strongest direct evidence in this group, with the important caveat that the strongest results come from in vitro studies on human cells rather than controlled human treatment trials.

A 2003 experiment on fibroblasts reported telomerase activation and telomere elongation, while the 2025 study by Al-Dulaimi reproduced telomere-related effects in normal and cancer human cell lines using more contemporary molecular methods. [10,11]

There is still no controlled clinical evidence showing significant telomere lengthening in humans after the use of Epitalon.

Mitochondrial bioenergetics

Elamipretide/SS-31 definitely has the strongest direct evidence in humans.

Human studies have measured mitochondrial ATP production capacity, exercise capacity, cardiac outcomes, and clinical endpoints in primary mitochondrial diseases. [19–23]

Most importantly, elamipretide became an FDA-approved drug in 2025 under the accelerated approval pathway for a specific subgroup of patients with Barth syndrome.

This approval is disease-specific. It does not confirm a role in healthy aging, general enhancement of mitochondrial function, or life extension.

NAD metabolism

NAD-targeted approaches have the strongest evidence in humans regarding the direct alteration of NAD-related biomarkers.

Numerous studies of NR and NMN in humans demonstrate an effect on the biochemical target, specifically an increase in NAD-related metabolites in the blood. [24–27]

However, a gap remains between biomarker change and healthspan improvement. Functional outcomes remain inconsistent, which is why recent reviews still define anti-aging efficacy in humans as unproven.

Human longevity

Regarding the actual extension of human life, none of these compounds have convincing evidence.

Epitalon has animal longevity studies, but in some models the effects mainly concerned maximum lifespan or late-life survival rather than mean lifespan, while other models showed limited effects.

NAD precursors have an extensive base of gerontological research in animals, but an extension of human lifespan has not been demonstrated.

Elamipretide has an advanced, disease-specific clinical development program, but no longevity study has been conducted showing a longer lifespan for healthy people.

DSIP has a history of sleep research, not evidence regarding lifespan.

Endoluten does not have a sufficiently clearly indexed evidence base to confirm its effect on longevity in humans.

Comparison of evidence in brief

The table shows why classifying these compounds as if they were competing for the same outcome can lead to erroneous conclusions.

Which compound generally has the strongest evidence in humans?

If „the strongest evidence in humans” means the most advanced conventional clinical development program, elamipretide clearly stands out. It has undergone Phase 2 and Phase 2/3 trials, has long-term observational data in humans with a rare mitochondrial disease, and received FDA accelerated approval in Barth syndrome in 2025. [19–23]

This does not mean it is the strongest longevity-related intervention. Its strongest evidence concerns a specific mitochondrial disease, rather than slowing down normal aging.

When it comes to evidence on human metabolic biomarkers, NAD precursors like NR and NMN have the largest contemporary clinical research base. Reviews now encompass dozens of human interventions, and repeated evidence shows that NAD-related biomarkers can be increased. [24–27] The uncertainty is whether changes in these biomarkers consistently translate into meaningful improvements in healthspan.

Regarding sleep, DSIP has more direct human studies than Epitalon, although this evidence is much weaker by modern clinical standards. [3–5]

The apparent advantage relates to the directness of measurements rather than proof of efficacy. DSIP studies evaluated sleep itself, but they were small, used historical intravenous protocols, and yielded conflicting objective and subjective results. They do not determine a reliable onset time, do not confirm the efficacy of a modern nasal or subcutaneous product, nor do they support long-term use for insomnia.

Regarding telomere biology, Epitalon has more direct experimental evidence, but the strongest relevant results remain cellular rather than clinical. [10,11]

In the case of Endoluten, the main issue is the attribution of evidence. Without a clearly indexed set of peer-reviewed clinical studies specific to Endoluten and a detailed molecular characterization, claims derived from studies on Epitalon or Epithalamin should not be considered direct evidence regarding Endoluten.

Do stronger mechanistic evidences mean better evidence regarding longevity?

No. A compound may have a clearly demonstrated biological mechanism while simultaneously showing no effect on human aging or lifespan. Telomere length, mitochondrial ATP production, NAD concentrations, melatonin rhythms, and sleep architecture are various surrogate endpoints, and changing a single biomarker does not automatically mean extending human life or slowing down aging.

This principle is crucial when comparing compounds related to longevity.

Elamipretide is a clear example. The peptide has a well-developed mitochondrial mechanism involving cardiolipin and has demonstrated a measurable impact on mitochondrial bioenergetics in humans. [18,22] Its clinical development has also progressed far enough to have obtained regulatory approval for a specific disease. Neither of these facts proves an extension of lifespan in healthy adults.

NAD research shows the same distinction. NR and NMN can consistently alter NAD-related metabolites in humans, while improvements in glucose metabolism, muscle function, vascular outcomes, and other healthspan-related parameters remain inconsistent. [24–27]

Epitalon shows a translational problem from a different perspective. The peptide can influence telomere maintenance pathways in cultured cells, but there is still a large gap between a telomere assay in fibroblasts and the extension of human survival.

DSIP similarly shows that even a direct impact on sleep-related physiology does not necessarily translate into a clinically useful method for treating sleep disorders.

Therefore, the most scientifically grounded comparison of longevity-related compounds separates:

targeting the mechanistic target

from

physiological improvement

from

clinical benefit

from

improvement of healthspan

from

extension of life.

These results are not interchangeable.

Frequently asked questions about Epitalon, DSIP, SS-31, and NAD+

Is DSIP better than Epitalon for sleep?

DSIP has more direct human sleep studies because controlled trials measured sleep latency, sleep efficiency, and parameters of individual sleep stages following DSIP administration. [3–5] However, the studies were small, and subsequent work showed that the clinical benefit was weak or of limited significance. Epitalon studies are more indirect and focus mainly on melatonin and circadian rhythm regulation rather than controlled insomnia outcomes.

The comparison therefore depends on the meaning of the word „better.” DSIP has a more direct history of sleep research, but neither of these peptides has been recognized as a modern approved treatment for insomnia. DSIP also lacks a confirmed receptor, a validated onset time in humans, or a demonstrated equivalence between the historically used intravenous route and products promoted for use via other routes.

Does DSIP reliably increase deep sleep?

There is no consistent evidence in humans showing that native DSIP reliably increases deep or slow-wave sleep. Some studies have reported changes in total sleep time or NREM sleep, but one controlled study showed that the increase was primarily in stage 2 rather than stages 3 and 4. Rat study results regarding phosphorylated DSIP refer to a chemically modified analogue and cannot confirm the effects of native DSIP in humans. [3–5]

Does DSIP lower cortisol?

Not in a predictable way based on available evidence. Human and animal studies suggest that DSIP may influence the regulation of ACTH, cortisol, or corticosterone under specific experimental conditions, but they do not confirm a reliable cortisol-lowering effect or a clinically validated mechanism for treating stress. [17]

What is the half-life of DSIP?

No validated human plasma elimination half-life has been established. The frequently cited value of about 15 minutes originates from peptide degradation observed in an in vitro system with brain tissue, rather than from a human pharmacokinetic study. It cannot be used as a clinical rule for timing or frequency of administration.

Is phospho-DSIP the same as DSIP?

No. Phospho-DSIP is DSIP modified by phosphorylation at the Ser7 position. In selected studies on rats, it induced sleep-related effects, but native DSIP and phospho-DSIP are distinct research interventions. Evidence concerning one form should not be automatically applied to the other.

Can Epitalon and DSIP be combined?

No robust peer-reviewed study evaluating the combination of Epitalon and DSIP has been identified. Their distinct research profiles may provide a theoretical rationale for investigating such a combination, but no established evidence exists regarding synergy, optimal ratio, better sleep outcomes, pharmacokinetic compatibility, or the long-term safety of the combination.

Does DSIP prolong life?

Human lifespan extension with DSIP has not been demonstrated. Its primary historical research focuses on sleep, electrophysiology, neuroendocrine signaling, and related physiological functions, rather than controlled longevity outcomes. Therefore, its presence in contemporary discussions of „longevity peptides” should not be interpreted as evidence that it extends human life.

Is SS-31 the same as elamipretide?

Yes. SS-31 is a developmental name commonly associated with the mitochondria-targeted peptide currently known as elamipretide. Its best-known mechanism involves cardiolipin and mitochondrial bioenergetics, and in 2025 the FDA granted elamipretide accelerated approval for a specific indication regarding Barth syndrome. [18,23]

Does SS-31 have proven anti-aging effects?

No. Elamipretide has an extensive base of human mitochondrial studies and an approved indication for Barth syndrome, but it has not been recognized as an anti-aging therapy or a method for extending human life. In a study involving older adults, an acute improvement in the energetic capacity of skeletal muscle mitochondria was observed, which constitutes a mechanistic physiological endpoint rather than evidence of slower aging or lifespan extension. [22]

Is NAD+ a peptide?

No. NAD+ is nicotinamide adenine dinucleotide, a dinucleotide cofactor involved in cellular redox metabolism and signaling. Chemically and biologically, it differs from Epitalon, DSIP, and elamipretide. Most modern human studies regarding „NAD boosting” have evaluated precursors such as NR and NMN, rather than peptide compounds.

Does NAD+ have better research support than Epitalon?

NAD-targeted approaches, particularly NR and NMN, have a larger modern human clinical literature and stronger evidence regarding the modulation of NAD-related biomarkers. Epitalon has distinctive cellular evidence concerning telomerase and telomeres, but significantly fewer modern clinical studies. Neither of these evidence bases supports human life extension or clinically proven general anti-aging effects.

Is Endoluten the same as Epitalon?

No. Epitalon is a chemically defined tetrapeptide AEDG. Endoluten is generally described as a low-molecular-weight peptide complex derived from the pineal gland, rather than a single defined peptide. Evidence obtained using Epitalon or the older pineal preparation Epithalamin should not automatically be treated as direct evidence regarding Endoluten.

Which longevity-related peptide is the strongest?

None of the peptides discussed here have shown a general extension of human lifespan. Elamipretide has the strongest conventional evidence regarding clinical development, but this pertains to mitochondrial diseases rather than longevity. Epitalon has characteristic cellular studies related to telomeres, whereas DSIP has direct, yet weak, historical evidence regarding human sleep. The meaning of the term „strongest” therefore depends on the outcome being compared.

Do Epitalon, DSIP, SS-31, and NAD+ work better together?

This has not been established. These compounds affect various biological systems, but theoretical complementarity does not prove synergy. To confirm a superior effect of the combination, controlled trials would need to compare each intervention against the combination while assessing pharmacokinetics, safety, and predetermined outcomes.

Limitations of longevity-related peptide comparisons

The first limitation is the category itself. Epitalon, DSIP, and elamipretide are peptides, but NAD+ is not, whereas Endoluten is better described as a peptide complex rather than a single molecule with a defined sequence. Grouping them under the term „longevity peptides” reflects modern search engine user behavior more than chemical classification.

Another limitation is the mismatch of endpoints. Epitalon research focuses on telomeres and pineal gland biology; DSIP research focuses on sleep; elamipretide directly affects mitochondrial bioenergetics; while NAD precursor studies measure metabolic and NAD-related outcomes. Comparing these compounds solely based on the number of publications, without considering what was actually measured, can lead to erroneous conclusions.

The third limitation is the difference between biomarkers and clinically relevant outcomes. Epitalon may affect telomeres in cultured cells, NR and NMN can increase the level of NAD-related metabolites, elamipretide can affect mitochondrial function, and DSIP can alter certain sleep parameters. None of these results automatically prove slower biological aging.

The fourth limitation concerns the age and quality of the evidence. DSIP is unusual because there are direct human clinical trials, but many of them were conducted in the 1980s on very small samples. The literature on Epitalon includes many older studies and a significant concentration of work originating from Khavinson's research network. Elamipretide has a more contemporary randomized clinical trial program, whereas NAD precursor research is extensive but heterogeneous.

In the case of DSIP, the route of administration, formulation, and molecular form further limit interpretation. Historical intravenous studies cannot validate modern nasal, oral, or subcutaneous products, and results concerning phospho-DSIP or modified analogues cannot be treated as evidence regarding native DSIP. The lack of modern pharmacokinetic programs, formulation studies, dose-ranging studies, and long-term safety leaves significant uncertainty even where older evidence of biological activity has been reported.

The fifth limitation is the specificity of the indication. The FDA approval of elamipretide in Barth syndrome represents an important milestone in terms of evidence, but it cannot be generalized to healthy individuals seeking mitochondrial or longevity-related effects. Similarly, studies on NR or NMN demonstrating an effect on a biochemical target cannot be translated into proof that a direct NAD+ infusion extends lifespan.

The sixth limitation concerns Endoluten. Search and product terminology often groups it with Epithalamin and Epitalon despite significant differences in chemical definition and evidence attribution. Until peer-reviewed studies specific to Endoluten clearly characterize the material and evaluate it independently, claims borrowed from other preparations require caution.

Finally, evidence regarding combinations is virtually absent. Search phrases involving Epithalon + DSIP or multi-component stacks related to longevity reflect user interest rather than established protocols. The diversity of mechanisms may justify studying combinations, but it cannot replace direct research on these mixtures.

Applications

Epitalon, DSIP, SS-31/elamipretide, NAD+, and Endoluten occupy very different positions in aging and longevity research. Distinctive evidence regarding Epitalon includes telomerase, telomeres, pineal gland biology, and experimental aging studies. DSIP has been the subject of direct human sleep studies, but reported benefits have been inconsistent and often considered clinically minor. Elamipretide has the strongest conventional clinical development program and a currently FDA-approved indication, but it specifically targets Barth syndrome rather than aging. NAD-targeted interventions, particularly NR and NMN, have the broadest contemporary human biomarker literature, while clinically meaningful anti-aging effects remain uncertain. Endoluten has a much less clearly attributable peer-reviewed evidence base than chemically defined Epitalon.

The expanded body of evidence regarding DSIP leads to the same conclusion. Historical studies demonstrate biological and sleep-related activity under certain conditions, but do not confirm repeatable efficacy in treating insomnia, a confirmed receptor mechanism, a validated human half-life, predictable cortisol reduction, or human life extension. When interpreting the literature, results regarding intravenous DSIP, phospho-DSIP, and contemporary unapproved products should be considered separately.

Most importantly, none of these compounds have been shown to extend normal human lifespan. The strongest evidence relates to narrower outcomes—sleep measurements for DSIP, mitochondrial disease and bioenergetics for elamipretide, NAD-related biomarkers for NR/NMN, and cellular telomeric mechanisms for Epitalon.

For this reason, the more scientifically useful question is not „Which longevity-related peptide is best?”, but rather: „Which compound has direct evidence regarding the specific biological or clinical outcome in question?”.

Disclaimer

The article is for educational and scientific-informational purposes only and does not constitute medical advice, dosage guidelines, therapeutic recommendations, product selection advice, or a recommendation for the use of Epitalon, DSIP, SS-31/elamipretide, NAD+, Endoluten, or any combination of these compounds. Their evidence bases vary significantly, and preclinical, cellular, or biomarker results should not be interpreted as evidence of anti-life-extending or anti-aging effects in humans. Elamipretide has a specific FDA-approved indication for certain patients with Barth syndrome, and this should not be generalized to healthy aging or longevity. Experimental doses and routes of administration described in the cited literature represent research details, not instructions for self-administration.

References

[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691.
https://doi.org/10.3390/ijms26062691

[2] Schoenenberger, G. A., Maier, P. F., Tobler, H. J., Wilson, K., & Monnier, M. (1978). The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Archiv, 376(2), 119–129.
https://doi.org/10.1007/BF00581575

[3] Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy and Toxicology, 19(8), 341–345.
https://pubmed.ncbi.nlm.nih.gov/6895513/

[4] Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919

[5] Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/

[6] Schoenenberger, G. A. (1984). Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). European Neurology, 23(5), 321–345. https://doi.org/10.1159/000115711

[7] Vinten, K. T., Trętowicz, M. M., Coskun, E., van Weeghel, M., Cantó, C., Zapata-Pérez, R., Janssens, G. E., & Houtkooper, R. H. (2025). NAD+ precursor supplementation in human ageing: Clinical evidence and challenges. Nature Metabolism, 7(10), 1974–1990.
https://doi.org/10.1038/s42255-025-01387-7

[8] Khavinson, V. K., Kopylov, A. T., Vaskovsky, B. V., Ryzhak, G. A., & Linkova, N. S. (2017). Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bulletin of Experimental Biology and Medicine, 164(1), 41–43.
https://doi.org/10.1007/s10517-017-3922-8

[9] National Center for Biotechnology Information. Delta Sleep-Inducing Peptide. PubChem CID 68816.
https://pubchem.ncbi.nlm.nih.gov/compound/68816

[10] Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592.
https://doi.org/10.1023/A:1025493705728

[11] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x

[11a] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2026). Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 27(1), Article 1. https://doi.org/10.1007/s10522-025-10326-8

[12] Khavinson, V. K., Bondarev, I. E., Butyugov, A. A., & Smirnova, T. D. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine, 137(5), 503–506. https://doi.org/10.1023/B:BEBM.0000038164.49947.8C

[13] Khavinson, V. K., Lezhava, T. A., Monaselidze, J. R., Jokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Trofimova, S. V. (2003). Peptide Epitalon activates chromatin at old age. Neuro Endocrinology Letters, 24(5), 329–333.
https://pubmed.ncbi.nlm.nih.gov/14647006/

[14] Goncharova, N. D., Khavinson, V. K., & Lapin, B. A. (2001). Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine, 131(4), 394–396.
https://doi.org/10.1023/A:1017928925177

[15] Khavinson, V. K., Linkova, N. S., Kvetnoy, I. M., Kvetnaia, T. V., Polyakova, V. O., & Korf, H.-W. (2012). Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture. Bulletin of Experimental Biology and Medicine, 153(2), 255–258.
https://doi.org/10.1007/s10517-012-1689-5

[16] Djeridane, Y., Khavinson, V. K., Anisimov, V. N., & Touitou, Y. (2003). Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. Journal of Endocrinological Investigation, 26(3), 211–215.
https://doi.org/10.1007/BF03345159

[17] Scherschlicht, R., Aeppli, L., Polc, P., & Haefely, W. (1984). Some pharmacological effects of delta-sleep-inducing peptide (DSIP). European Neurology, 23(5), 346–352.
https://doi.org/10.1159/000115712

[18] Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., Seshan, S. V., Pardee, J. D., & Szeto, H. H. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261. https://doi.org/10.1681/ASN.2012121216

[18a] Birk, A. V., Chao, W. M., Bracken, C., Warren, J. D., & Szeto, H. H. (2014). Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology, 171(8), 2017–2028. https://doi.org/10.1111/bph.12468

[19] Karaa, A., Haas, R., Goldstein, A., Vockley, J., Weaver, W. D., & Cohen, B. H. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 90(14), e1212–e1221. https://doi.org/10.1212/WNL.0000000000005255

[20] Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B. H. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle, 11(4), 909–918.
https://doi.org/10.1002/jcsm.12559

[21] Butler, J., Khan, M. S., Anker, S. D., Fonarow, G. C., Kim, R. J., Nodari, S., O’Connor, C. M., Pieske, B., Pieske-Kraigher, E., Sabbah, H. N., Senni, M., Voors, A. A., Udelson, J. E., Carr, J., Gheorghiade, M., & Filippatos, G. (2020). Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure, 26(5), 429–437.
https://doi.org/10.1016/j.cardfail.2020.02.001

[22] Roshanravan, B., Liu, S. Z., Ali, A. S., Shankland, E. G., Goss, C., Amory, J. K., Robertson, H. T., Marcinek, D. J., & Conley, K. E. (2021). In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLOS ONE, 16(7), e0253849. https://doi.org/10.1371/journal.pone.0253849

[23] Thompson, W. R., Hornby, B., Manuel, R., Bradley, E., Laux, J., Carr, J., & Vernon, H. J. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 23(3), 471–478.
https://doi.org/10.1038/s41436-020-01006-8

[24] Zhang, J., Wang, H.-L., Lautrup, S., Nilsen, H. L., Treebak, J. T., Watne, L. O., Selbæk, G., Wu, L. E., Omland, T., Pirinen, E., et al. (2025). Emerging strategies, applications and challenges of targeting NAD+ in the clinic. Nature Aging, 5(9), 1704–1731. https://doi.org/10.1038/s43587-025-00947-6

[25] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057

[26] Freeberg, K. A., Udovich, C. A. C., Martens, C. R., Seals, D. R., & Craighead, D. H. (2023). Dietary supplementation with NAD+-boosting compounds in humans: Current knowledge and future directions. The Journals of Gerontology: Series A, 78(12), 2435–2448. https://doi.org/10.1093/gerona/glad106

[27] Bhasin, S., Seals, D., Migaud, M., Musi, N., & Baur, J. A. (2023). Nicotinamide adenine dinucleotide in aging biology: Potential applications and many unknowns. Endocrine Reviews, 44(6), 1047–1073. https://doi.org/10.1210/endrev/bnad019

[27a] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x

[28] Khavinson, V. K., Linkova, N. S., & Tarnovskaya, S. I. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 162(2), 288–292.
https://doi.org/10.1007/s10517-016-3596-7